Screening for hepatocellular carcinoma: summary of current guidelines up to 2018

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related to worldwide death with a great geographical variation. To be eligible for curative therapy at the time of diagnosis is important. However, the majority of cases are diagnosed at late stages. This can be achieved with applicable screening modalities. Until now, many organizations around the world have developed guidelines according to their own evidence-based data for screening of HCC. The purpose of this article is to review the screening modalities of HCC to assist gastroenterologists and providers involved in the management of HCC.

Keywords

Hepatocellular carcinoma / screening / guidelines / surveillance

References

[1] International Agency for Research on Cancer. GLOBOCAN 202: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 202. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. [Last accessed on 10 Aug 2018]

[2] European Association for the Study of the Liver.EASL Clinical Practice Guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[3] El-Serag H.Epidemiology of hepatocellular carcinoma in the United States: where are we? where do we go?.Hepatology2014;60:1767-75 PMCID:PMC4211957

[4] Torre LA,Ward EM.Global cancer incidence and mortality rates and trends--an update.Cancer Epidemiol Biomarkers Prev2016;25:16-27

[5] Altekruse SF,Reichman MA.Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.J Clin Oncol2009;27:1485-91 PMCID:PMC2668555

[6] Sheldon WH.Cirrhosis following infectious hepatitis; a report of five cases, in two of which there was superimposed primary liver cell carcinoma.Arch Intern Med (Chic)1948;81:666-89

[7] Nikulina D,Galimzyanov K.Fifty years of discovery of alpha-fetoprotein as the first tumor marker.Srp Arh Celok Lek2015;143:100-4

[8] Tang ZY.Screening and early treatment of primary liver cancer--with special reference to the east part of China.Ann Acad Med1980;9:234-9

[9] Altekruse SF,Cucinelli JE.Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States.Am J Gastroenterol2014;109:542-53 PMCID:PMC4148914

[10] Jemal A,Center MM,Ward E.Global cancer statistics.CA Cancer J Clin2011;61:69-90

[11] Akinyemiju T,Ahmed M,Alemayohu MA,Al-Raddadi R,Amoako Y,Ayele TA,Bensenor I,Bhutta Z,Chitheer A,Cowie B,Dandona R,Dicker D,Ekwueme DU,Fischer F,Hancock J,Hotez P,Kasaeian A,Khang YH,Kutz M,Lopez A,Malekzadeh R,Meier T,Mokdad A,Nagel G,Nguyen G,Patton G,Pourmalek F,Radfar A,Salomon JA,Sartorius B,Sawhney M,Shackelford K,Sun J,Topór-Mądry R,Ukwaja,Vollset SE,Wakayo T,Werdecker A,Younis M,Zaidi Z,Murray CJL,Fitzmaurice C.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level.JAMA Oncol2017;3:1683-91

[12] Wong GL,Tan GM,Lai WK,Mak MS,Sung JJ.Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis.Liver Int2008;28:79-87

[13] Wong GL.Optimal surveillance program for hepatocellular carcinoma - getting ready, but not yet.World J Hepatol2015;7:2133-5 PMCID:PMC4550867

[14] Guideline. Available from: https://www.ldoceonline.com/dictionary/guideline.[Last accessed on 10 Aug 2018]

[15] Cancer European Organisation For Research And Treatment Of.EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2012;56:908-43

[16] Llovet JM,Bruix A.Hepatocellular carcinoma.Lancet2003;362:1907-17

[17] El-Serag HB.Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.Gastroenterology2007;132:2557-76

[18] Forner A,Bruix J.Hepatocellular carcinoma.Lancet2018;391:1301-14

[19] Sangiovanni A,Fasani P,Romeo R,Del Ninno E,Colombo M.The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients.Hepatology2006;43:1303-10

[20] Hung TH,Hsu CN,Tsai KL,Wang JW,Yuan LT,Yang SC,Hsu PI,Chuah SK.Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan.PLoS One2017;12:e0181858 PMCID:PMC5524412

[21] Fattovich G,Zagni I.Hepatocellular carcinoma in cirrhosis: incidence and risk factors.Gastroenterology2004;127:S35-50

[22] Flemming JA,Vittinghoff E,Terrault NA.Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model.Cancer2014;120:3485-93 PMCID:PMC4553222

[23] Lok AS,Morgan TR,Sterling RK,Everson GT,Lee WM,Dienstag JL,Morishima C.Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.Gastroenterology2009;136:138-48 PMCID:PMC3749922

[24] Fateen W.Screening for hepatocellular carcinoma: patient selection and perspectives.J Hepatocell Carcinoma2017;4:71-9 PMCID:PMC5440035

[25] Sarasin FP,Hadengue A.Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis.Am J Med1996;101:422-34

[26] Heimbach JK,Finn RS,Abecassis MM,Zhu AX,Marrero JA.AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology2018;67:358-80

[27] Bruix J.Management of hepatocellular carcinoma: an update.Hepatology2011;53:1020-2 PMCID:PMC3084991

[28] Sherman M,Maroun J,Knox JJ,Guindi M,Kachura JR,Gill S,Chaudhury P,Valenti D,Wong R.Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.Curr Oncol2011;18:228-40 PMCID:PMC3185900

[29] Burak KW.Hepatocellular carcinoma: consensus, controversies and future directions: a report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting.Can J Gastroenterol Hepatol2015;29:178-84

[30] Omata M,Kokudo N,Lee JM,Tateishi R,Chawla YK,Jafri W,Ohki T,Chen PJ,Lesmana LA,Obi S,Sarin SK.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.Hepatol Int2017;11:317-70 PMCID:PMC5491694

[31] Xie DY,Zhou J,Gao Q.Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma.Hepatobiliary Surg Nutr2017;6:387-96 PMCID:PMC5756765

[32] Kokudo N,Akahane M,Izumi N,Uemoto S,Kawasaki S,Kudo M,Takayama T,Fukuda T,Matsuyama Y,Arii S,Makuuchi M.Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines).Hepatol Res2015;45:12464

[33] Kudo M.Clinical practice guidelines for hepatocellular carcinoma differ between Japan, United States, and Europe.Liver Cancer2015;4:85-95 PMCID:PMC4439783

[34] Kudo M,Izumi N.JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan.Liver Cancer2014;3:458-68 PMCID:PMC4531423

[35] Forner A,Varela M,Feliu J,Sastre J,Llovet JM,Sangro B,Ayuso C,Tabernero J.Diagnosis and treatment of hepatocellular carcinoma.Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. Med Clin2016;146:511

[36] Verslype C,Rougier P.Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines.Ann Oncol2012;23:41-8

[37] Sastre J,García-Foncillas J,López C,Rodriguez-Salas N,Salud A.Clinical guideline SEOM: hepatocellular carcinoma.Clin Transl Oncol2015;17:988-95 PMCID:PMC4689753

[38] Schütte K,Poranzke J,Bornschein J,Arend J,Malfertheiner P.Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver.BMC Gastroenterol2014;14:117 PMCID:PMC4098694

[39] Trevisani F,Santi V,Bernardi M.Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal.Dig Liver Dis2010;42:341-7

[40] Lee YC,Yang YC,Hashibe M.Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer.Int J Epidemiol2009;38:1497-511

[41] Papatheodoridis G,Sypsa V,Buti M,Calleja JL,Manolakopoulos S,Gatselis N,Savvidou S,Hansen BE,Galanis K,Colombo M,Janssen HL.PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.J Hepatol2016;64:800-6

[42] Sheu JC,Chen DS,Lai MY,Hsu HC,Yang PC,Lin JT.Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications.Gastroenterology1985;89:259-66

[43] Trinchet JC,Bourcier V,Henrion J,Roulot D,Hillaire S,Ollivier I,Mathurin P,Vilgrain V,Beaugrand M.Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis:a randomized trial comparing 3- and 6-month periodicities.Hepatology2011;54:1987-97

[44] Bolondi L.Screening for hepatocellular carcinoma in cirrhosis.J Hepatol2003;39:1076-84

[45] Singal A,Waljee A,Higgins P,Marrero JA.Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.Aliment Pharmacol Ther2009;30:37-47

[46] Biselli M,Gramenzi A,Cucchetti A,D'Angelo M,Giannini EG,Ciccarese F,Bernardi M.A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis.Br J Cancer2015;112:69-76 PMCID:PMC4453600

[47] Johnson P,Kagebayashi C,Teng M,Yeo W,Lai P,Tada T,Kumada T.Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance.Br J Cancer2017;116:441-7 PMCID:PMC5318967